Cargando…

Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma

Cirmtuzumab may enhance the therapeutic activity of ibrutinib by inhibiting ROR1-dependent signaling pathway in patients with chronic lymphocytic leukemia (CLL). Mantle cell lymphoma (MCL) is B-cell malignancy that also expresses ROR1. In this study, we found that the plasma of patients with MCL had...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Jian, Chen, Yun, Chen, Liguang, Zhang, Ling, Rassenti, Laura Z., Widhopf, George F., Kipps, Thomas J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973864/ https://www.ncbi.nlm.nih.gov/pubmed/29872501 http://dx.doi.org/10.18632/oncotarget.25340

Ejemplares similares

Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib
por: Yu, J, et al.
Publicado: (2017)

Wnt5a enhances proliferation of chronic lymphocytic leukemia and ERK1/2 phosphorylation via a ROR1/DOCK2-dependent mechanism
por: Hasan, Md Kamrul, et al.
Publicado: (2020)

Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells
por: Hasan, Md Kamrul, et al.
Publicado: (2018)

Wnt5a induces ROR1 to associate with 14-3-3ζ for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells
por: Yu, J, et al.
Publicado: (2017)

Cryptococcal meningoencephalitis in patients with mantle cell lymphoma on ibrutinib
por: Sun, Kai, et al.
Publicado: (2018)

Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells
por: Hasan, M K, et al.
Publicado: (2017)

Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma
por: Li, Lingzhi, et al.
Publicado: (2022)

Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma
por: Zhao, Xiaohong, et al.
Publicado: (2017)

Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
por: Peterson, Derek, et al.
Publicado: (2014)

Ibrutinib Is Effective in the Treatment of Autoimmune Haemolytic Anaemia in Mantle Cell Lymphoma
por: Galinier, Aliénor, et al.
Publicado: (2017)

Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma
por: Zhao, Xiaohong, et al.
Publicado: (2021)

Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma
por: Portell, Craig A., et al.
Publicado: (2022)

Ibrutinib: Implications for Use in the Treatment of Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
por: McNally, Gretchen Anne, et al.
Publicado: (2015)

Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma
por: Maruyama, Dai, et al.
Publicado: (2016)

CD52 and OXPHOS—potential targets in ibrutinib-treated mantle cell lymphoma
por: Fuhr, Viktoria, et al.
Publicado: (2022)

CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma
por: Mohanty, Atish, et al.
Publicado: (2016)

NR4A1 inhibition synergizes with ibrutinib in killing mantle cell lymphoma cells
por: Li, Yangguang, et al.
Publicado: (2017)

A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia
por: Tucker, David L, et al.
Publicado: (2015)

Ibrutinib Caused Mediastinal Emphysema and Pneumothorax in the Treatment of a Patient with Mantle Cell Lymphoma
por: Tsutsumi, Yutaka, et al.
Publicado: (2019)

Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real‐world experience
por: Jeon, Young‐Woo, et al.
Publicado: (2019)

PB2072: EFFICACY AND SIDE EFFECTS OF IBRUTINIB IN RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA
por: Basturk, A., et al.
Publicado: (2022)

Rac1 is a novel therapeutic target in mantle cell lymphoma
por: Tian, Tian, et al.
Publicado: (2018)

Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment
por: Rudelius, Martina, et al.
Publicado: (2018)

Diffuse Alveolar Hemorrhage Secondary to Ibrutinib Therapy in a Patient With Refractory Mantle Cell Lymphoma
por: Locke, Clifford B, et al.
Publicado: (2020)

A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma
por: Qualls, David, et al.
Publicado: (2022)

High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia
por: Ghia, Emanuela M., et al.
Publicado: (2022)

Dual targeting of PI3K and BCL‐2 overcomes ibrutinib resistance in aggressive mantle cell lymphoma
por: Ye, Haige, et al.
Publicado: (2022)

Ibrutinib Plus R-ICE Induces Remission in Blastoid Variant Mantle Cell Lymphoma with CNS Relapse
por: Oh, Timothy S., et al.
Publicado: (2022)

USP14 promotes the malignant progression and ibrutinib resistance of mantle cell lymphoma by stabilizing XPO1
por: Zhang, Ye, et al.
Publicado: (2023)

Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study
por: Wang, Michael, et al.
Publicado: (2021)

Targeting Wnt pathway in mantle cell lymphoma-initiating cells
por: Mathur, Rohit, et al.
Publicado: (2015)

Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma
por: Maruyama, Dai, et al.
Publicado: (2019)

Ibrutinib Treatment of Mantle Cell Lymphoma Relapsing at Central Nervous System: A Case Report and Literature Review
por: Mannina, Donato, et al.
Publicado: (2017)

1092. Increased Risk of Serious Infections in Mantle Cell Lymphoma Versus Other Hematologic Malignancies in Patients on Ibrutinib
por: Holowka, Thomas, et al.
Publicado: (2020)

Does Ibrutinib impact outcomes of viral infection by SARS-CoV-2 in mantle cell lymphoma patients?
por: Alsuliman, Tamim, et al.
Publicado: (2021)

HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton’s Tyrosine Kinase Inhibitor Ibrutinib
por: Lu, Ziwen, et al.
Publicado: (2022)

Inhibition of LINK-A lncRNA overcomes ibrutinib resistance in mantle cell lymphoma by regulating Akt/Bcl2 pathway
por: Zhang, Ye, et al.
Publicado: (2021)

A case of new‐onset cardiomyopathy and ventricular tachycardia in a patient receiving ibrutinib for relapsed mantle cell lymphoma
por: Wallace, Natalie, et al.
Publicado: (2016)

Ibrutinib Treatment through Nasogastric Tube in a Comatose Patient with Central Nervous System Localization of Mantle Cell Lymphoma
por: Alsuliman, Tamim, et al.
Publicado: (2018)

Distal chromosome 1q aberrations and initial response to ibrutinib in central nervous system relapsed mantle cell lymphoma
por: Hansen, Marcus Høy, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r272ksvpge76bn1l7ppjh36nbd